Once effective ositinib can live a few years can not be determined, and clinical stage, treatment effect and patient status and so on, it is recommended that standardized treatment.
Ocitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. It is used as postoperative adjuvant therapy for patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation or as first-line therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
It may also be used for the treatment of adult patients with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment with an EGFR tyrosine kinase inhibitor (TKI) and who have been tested and confirmed to have a positive EGFR T790M mutation.
Application of ositinib will prolong the survival time, the specific survival time and patient status, staging and so on is very related to the specific time can not be determined.
Ositinib adverse reactions: can cause interstitial lung disease, congenital long QT interval syndrome patients should avoid using this product. Patients with acute attacks of keratitis or worsening signs such as ocular inflammation, photophobia and tearing, and blurred vision need to be referred to the orbital clinic. Contraindications: It is contraindicated in people who are allergic to ocitinib.
Taking OXITINI if there is any discomfort , it is recommended to promptly go to the hospital, a clear diagnosis and treatment, so as not to delay the condition.